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Antibodies  to selected  Plasmodium  falciparum  merozoite  antigens  are  often  reported  to  be associated  with
protection  from  malaria  in one  epidemiological  cohort,  but  not  in  another.  Here,  we  sought  to understand
this paradox  by  exploring  the  hypothesis  that  a threshold  concentration  of antibodies  is  necessary  for
protection.  We  analyzed  data  from  two independent  cohorts  along  the  Kenyan  coast,  one  in  which  anti-
bodies to  AMA1,  MSP-2  and  MSP-3  were  associated  with  protection  from  malaria  (Chonyi)  and  another
in which  this  association  was  not  observed  (Junju).  We  used  a  malaria  reference  reagent  to  standard-
ize  antibody  measurements  across  both  cohorts,  and  applied  statistical  methods  to  derive  the  threshold
concentration  of  antibodies  against  each  antigen  that  best  correlated  with  a  reduced  risk  of  malaria  (the
protective  threshold),  in  the  Chonyi  cohort.  We  then  tested  whether  antibodies  in Junju  reached  the  pro-
tective  threshold  concentrations  observed  in  the  Chonyi  cohort.  Except  for children  under  3 years,  theoncentrations
mmuno-epidemiology
age-matched  proportions  of children  achieving  protective  threshold  concentrations  of  antibodies  against
AMA1  and  MSP-2  were  signiﬁcantly  lower  in  Junju  compared  to  Chonyi  (Fishers  exact  test,  P  < 0.01).  For
MSP-3,  this  difference  was  signiﬁcant  only  among  4–5  year  olds.  We  conclude  that  although  antibodies
are  commonly  detected  in malaria  endemic  populations,  they  may  be present  in  concentrations  that  are
insufﬁcient  for  protection.  Our  results  have  implications  for the  analysis  and  interpretation  of  similar
data  from  immuno-epidemiological  studies.
2013© 
. Introduction
Antibodies play an important role in mediating protection
gainst clinical malaria. Puriﬁed total IgG obtained from malaria-
mmune African adults was successfully used to treat children and
dults hospitalized with malaria, while control sera from adults
ot exposed to malaria had no protective effect [1–3]. Identifying
he target(s) of these “protective” antibodies continues to be a pri-
rity for malaria vaccine development. Immuno-epidemiological
tudies are widely used to assess the potential protective efﬁcacy
f antibodies against Plasmodium falciparum antigens in humans.
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However, such studies have often yielded inconsistent results with
some studies demonstrating a protective role for antibodies to a
speciﬁc antigen, while others do not [4]. One important reason for
this may  be the lack of a standardized approach to the reporting
of antibody concentrations, and the methods used for their anal-
ysis [4,5]. While there is reasonable agreement that high levels of
antibodies are better indicators of protection than sero-positivity,
the deﬁnition of “high” varies considerably between studies [5–10],
making it difﬁcult to compare ﬁndings from different sites.
Here, we  investigated why antibodies appeared to be protec-
tive in some settings but not in others. Speciﬁcally, we tested the
hypothesis that a threshold concentration of antibody was  required
for protection and that in some settings, although antibodies were
present, their concentrations were below the thresholds required
for protection. Quantitative correlates of protection have been
Open access under CC BY license. reported for vaccine-induced antibodies against many infectious
diseases [11]. For malaria, although antibodies to several speciﬁc
antigens have been shown to correlate with protection from clini-
cal episodes of malaria [4], similar quantitative correlates have not
license. 
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et been deﬁned. In one study, the concept of an antigen-speciﬁc
hreshold concentration of antibodies that correlated best with pro-
ection against P. falciparum infection was explored [5] but not
pplied in subsequent studies [12,13]. In the study reported here,
e develop this concept by using data from one cohort to iden-
ify “protective thresholds”, deﬁned as the antibody concentrations
gainst speciﬁc antigens that best correlate with protection from
linical episodes of malaria. We  subsequently tested the validity of
hese thresholds in an independent cohort.
Our previous studies have shown that antibodies to speciﬁc
erozoite antigens were associated with protection from clinical
pisodes of malaria in the Chonyi cohort [6,14–16]. In subsequent
tudies conducted in the same geographical area along the Kenyan
oast, but during a period of moderate transmission, antibodies to
he same panel of merozoite antigens were not associated with
rotection (data presented here). We  used a puriﬁed IgG prepa-
ation as a reference reagent to standardize the measurement of
ntibody concentrations in both cohorts, and statistical methods
o determine the relative IgG concentrations against each antigen
hat best correlated with protection in the Chonyi cohort. We  show
hat antibody concentrations in the moderate transmission cohort
ere below the thresholds required for protection.
. Materials and methods
.1. Study populations
.1.1. Chonyi cohort
The Chonyi cohort in Kiliﬁ, Kenya, has been extensively studied
6,14–22]. The parasite prevalence rate in children aged 2–10 years
PfPR2–10) [23] was 44% at the time of the study. For this report we
nalyzed 286 serum samples collected in October 2000 at the start
f a malaria transmission season from children aged 0–10 years.
hese children were subsequently followed up for 6 months for
linical episodes of malaria. In this area, the age-speciﬁc criteria
or deﬁning clinical episodes of malaria are established and are as
ollows: for children <1 year old, a temperature of >37.5 ◦C plus any
arasitaemia; for children >1 year old, a temperature of >37.5 ◦C
lus a parasitaemia of >2500/l [20]. Clinical episodes of malaria
ere monitored by both active and passive case detection. Trained
eld workers visited the participants every week whereby children
ith fever (axilliary temperature >37.5 ◦C) had a blood slide taken.
hildren with a positive test result were treated with antimalarial
rugs. In addition, parents were advised to report to a dedicated
utpatient clinic at Kiliﬁ District Hospital if their child developed
ymptoms of disease at any time.
.1.2. Junju cohort
Children aged 1–6 years in a second independent group, the
unju cohort, were originally recruited in 2005 [24] and have been
ollowed up as above, for clinical episodes of malaria [20,24].
n addition, trained ﬁeld workers were available in the village
o conduct passive surveillance. Children born into study house-
olds are continuously recruited into the cohort. Peak malaria
ransmission occurs during the rainy months of May–July and
ovember to December. Blood samples are collected annually dur-
ng a cross-sectional survey conducted at the beginning of the
alaria transmission season in May. The PfPR2–10 in Junju was  29%
t the time of sampling. Participants in the Junju cohort area live
pproximately 25 km away from those described above in the Cho-
yi cohort. We  analyzed 304 serum samples collected in May  2008
rom children aged 1–12 years. Data on 6 months of follow up in
he subsequent malaria transmission season are presented here.
The Kenyan national scientiﬁc and ethics committees reviewed
nd approved the studies.31 (2013) 3936– 3942 3937
2.2. Recombinant P. falciparum merozoite antigens
All antigens are based on P. falciparum and include the 19 Kilo-
Dalton C-terminal fragment of merozoite surface protein (MSP)-1
of the Wellcome parasite line [25], full-length recombinant apical
membrane antigen (AMA)-1 of the HB3 parasite line [26], MSP-2 of
the Dd2 parasite line [27] and MSP-3 of the 3D7  allelic type [6,28].
Responses to two fragments of Glutamate-rich protein (GLURP)
representing the N-terminal non-repeat region (GLURP-R0) and
C-terminal repeat region (GLURP-R2) were also analyzed [29].
2.3. Enzyme-Linked Immunosorbent Assay (ELISA)
Serum IgG responses to individual antigens were measured
using a well-established standard ELISA protocol [6,14–16]. Addi-
tionally, a puriﬁed IgG standard was incorporated into the assay
and allowed for the extrapolation of relative antibody concen-
trations. Eleven two-fold serial dilutions of a reference Malaria
Immune Globulin (MIG) reagent (Central Laboratory Blood Trans-
fusion Service SRC, Switzerland) [30] were included for every
antigen to generate a standard ELISA curve. This preparation con-
tains 50 mg/ml  of immunoglobulins (98% IgG) puriﬁed from a pool
of healthy Malawian adult plasma and was originally manufac-
tured to test its potential use as an adjunct therapy to quinine in
the treatment of cerebral malaria [30]. The four-parameter logis-
tic function was used to ﬁt the standard curve in GraphPad Prism
version 4.0 (GraphPad Software, San Diego, CA). ELISA OD values of
test samples were converted into relative antibody concentrations
using parameters estimated from the standard curve, assuming
the puriﬁed IgG preparation contained 50 arbitrary units (AU) of
antigen-speciﬁc antibodies. A pool of sera from Kiliﬁ adults was
included on every plate as a positive control. Sera from twenty
Europeans served as negative controls to determine cutoff val-
ues for seropositivity, deﬁned as mean optical density plus three
standard deviations. Responses to AMA1, MSP-2, and MSP-3 were
measured in both cohorts whereas those to MSP-119 and GLURP
were measured in the Chonyi cohort only.
2.4. Statistical analysis
Data analysis was performed using Stata 11 (StatCorp, TX).
A modiﬁed Poisson regression model was used as previously
described [6] to examine the effects of individual antibodies on the
outcome, deﬁned as a clinical episode of malaria during 6 months of
follow-up. Age and reactivity to parasite schizont extract were ﬁt-
ted as covariates in multivariate analyses, to minimize confounding
by parasite exposure. Age was ﬁtted as a categorical variable (age
bands of 0–3, 4–5, 6–7, 8–12 years), while reactivity to schizont
was  ﬁtted as a continuous variable. This model was  used for all the
analyses described below.
We used data from all children in the Chonyi cohort to estimate
the relative concentration of antibodies that best correlated with
clinical protection for each antigen as follows: (i) different antibody
concentrations were applied as cutoffs for high versus low respon-
ders over a range of increasing concentrations up to the maximum
concentration recorded against each antigen, (ii) a modiﬁed Pois-
son regression model was  used to calculate the risk ratio at each
cutoff value, (iii) the best ﬁtting model was selected using the log
pseudolikelihood [31]. The antibody concentrations that resulted
in the best ﬁtting models were designated as “protective thresh-
olds”. The protective thresholds were then used in two ways (i) to
compare age-matched antibody levels in the Chonyi versus Junju
cohorts and (ii) as cutoffs, comparing the clinical outcome of chil-
dren with levels above, versus below the threshold, for each antigen
in the Junju cohort.
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Table 1
A comparison of analyses based on antibody seropositivity, high antibody levels and protective thresholds in the Junju cohort.
AMA-1 MSP-2 MSP-3
Seropos High antibody
levels
Threshold Seropos High antibody
levels
Threshold Seropos High antibody
levels
Threshold
All individuals (N = 304)
Prevalence 67 21 6 31 25 10 26 18 8
%  (n/N) (203/304) (65/304) (17/304) (95/304) (77/304) (29/304) (80/304) (54/304) (23/304)
IgG  42 37 6 37 35 31 30 22 13
positivea (85/203) (24/65) (1/17) (35/95) (27/77) (9/29) (24/80) (12/54) (3/23)
IgG  40 42 43 43 43 42 45 45 43
negativeb (40/101) (101/239) (124/287) (90/209) (98/227) (116/275) (101/224) (113/250) (122/281)
Univariate 1.05 0.87 0.13 0.85 (0.62,1.16) 0.81 0.73 0.66 0.49 0.33
RR  (95% CI) (0.79,1.41) (0.61,1.24) (0.02,0.91) (0.57,1.14) (0.41,1.28) (0.46,0.95) (0.29,0.82) (0.11,0.95)
Multivariate 1.09 0.94 0.16 0.79 0.78 0.74 0.63 0.47 0.34
RR  (95% CI) (0.75,1.59) (0.65,1.36) (0.02,1.12) (0.57,1.08) (0.55,1.12) (0.42,1.29) (0.42,0.94) (0.27,0.81) (0.12,0.94)
Abbreviations: Seropos, seropositivity; Threshold, protective threshold; ND, not determined; RR, risk ratio.
The  risk of developing a clinical episode of malaria during the 6-month follow-up period was  compared in analyses based on antibody seropositivity, high antibody levels
and  protective thresholds. Data were ﬁtted to modiﬁed Poisson regression models, adjusting for age and reactivity to parasite schizont extract in multivariate analyses [6].
Signiﬁcant results at P < 0.05 are shown in bold.
a IgG seropositive, high antibody levels or above the protective threshold and developing malaria during follow-up.
b IgG seronegative, high antibody levels or below the protective threshold and developing malaria during follow-up.
Table 2
Cutoff values for antibody seropositivity, high antibody levels and protective thresholds in the Chonyi cohort.
Antigen Seropositivity cutoffa (AU) High levels cutoffb (AU) Protective thresholdc (AU) Protective efﬁcacyd (%) (Risk ratio; 95% CI)e
AMA-1 0.70 43.70 55.00 25 (0.75; 0.42–1.33)
MSP-2  7.40 18.50 19.00 43 (0.57; 0.32–1.00)
MSP-3  0.39 6.50 16.00 56 (0.44; 0.16–1.17)
GLURP-R0 7.90 ND 11.00 41 (0.59; 0.27–1.28)
GLURP-R2 4.30 5.90 8.00 40 (0.60; 0.31–1.18)
MSP-119 8.2 15.70 ND ND ND
Abbreviations: AU, arbitrary units; SD, standard deviation; ND, not determined.
A  protective threshold antibody concentration against MSP-119 could not be determined. A high antibody level cutoff could not be determined for GLURP-R0 because the
majority  of responses against this antigen were low.
a Seropositivity cutoff is deﬁned as the mean + 3SD response of sera from malaria naive donors for each antigen tested.
b High antibody level cutoff is deﬁned as the antibody concentration above which the risk of malaria was  lower than the population’s average risk of developing malaria
[6].
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d Protective efﬁcacy in analyses based on the protective threshold as a cutoff. Cal
e Risk ratios and 95% conﬁdence intervals applied in the calculation of protective
.5. Comparing analyses based on protective thresholds with
hose based on conventional cutoffs
Analyses using the protective threshold as a cutoff point were
ompared to conventional analyses where the cutoff is deﬁned as
1) seropositivity, deﬁned as the mean plus 3 standard deviations of
egative controls and (2) high versus low antibody levels, deﬁned
reviously by us as the ELISA OD level above which the risk of
alaria was lower than the population’s average risk of acquir-
ng a clinical episode of malaria [6]. Importantly, analyses based on
igh versus low antibody levels have been deﬁned differently in
ifferent immuno-epidemiological studies, but ultimately depend
n the range of ELISA OD reactivities observed in the population
nder test. In contrast, the protective threshold we  now propose is
 ﬁxed antibody concentration, which will not vary between study
opulations.
. Results
.1. Antibodies to merozoite antigens are not associated with
rotection in the Junju cohortChildren in the Junju cohort were sampled during a period of
oderate malaria transmission intensity. In spite of this, antigen-
peciﬁc antibodies were readily detectable in the cohort, and
ntibody prevalence was 67%, 31% and 26% for AMA1, MSP-2 andhe least log pseudolikelihood value in a modiﬁed Poisson regression model.
d as (1 − RR) × 100.
cyd.
MSP-3, respectively. Antibody levels increased signiﬁcantly with
age for all antigens tested (Pearson’s chi-square test for trend,
P < 0.05).
We  tested whether antibodies against these antigens were asso-
ciated with a lower risk of malaria in two  ways. For the ﬁrst analysis
we  used a cutoff that compared the outcome in children that were
seropositive (deﬁned as the mean plus three standard deviations of
non-malaria exposed European sera) to those that were seroneg-
ative for antibodies to these merozoite antigens. In the second
analysis, we compared children that had high levels of antibod-
ies (the ELISA OD level above which the risk of malaria was lower
than the population’s average risk of acquiring a clinical episode
of malaria) to those that had low antibody levels to each of the
antigens. In both these analyses, with the exception of MSP-3, anti-
bodies to these antigens were not associated with protection from
malaria (Table 1).
3.2. Identifying a threshold concentration of antibodies that best
correlates with a reduced risk of malaria
Next, we tested the hypothesis that the apparent lack of protec-
tion observed in the Junju cohort could be explained by insufﬁcient
antibody concentrations. To do this, we  used data from the Cho-
nyi cohort where antibodies to these antigens had previously been
studied and were known to correlate with protection from malaria
[6,14–16]. Using the puriﬁed IgG as a standard for measuring
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elative antibody concentrations, we determined for each antigen,
he relative IgG antibody concentration that best correlated with
rotection from malaria by selecting the model with the least log
seudolikelihood [31]. The antibody concentration thus derived
as designated the “protective threshold”, and it varied for dif-
erent antigens, resulting in protective efﬁcacies ((1 − RR) × 100) of
5–56% (Table 2). Notably, this threshold concentration was higher
han that deﬁned both by seropositivity and by high antibody levels
Table 2). ELISA OD’s against the R0 fragment of GLURP were highly
kewed to the right and it was not possible to deﬁne high levels as
escribed above. A protective threshold could not be identiﬁed for
ntibodies against MSP-119.
.3. Antibody concentrations are below protective thresholds in
unju cohort
We  then compared age-matched antibody concentrations in
oth Chonyi and Junju in relation to the protective thresholds
or each antigen. Median IgG levels to AMA1, MSP-2 and MSP-3
ere signiﬁcantly lower in the Junju cohort compared to those
n the Chonyi cohort across all age groups (Mann–Whitney test,
 < 0.01) except for the youngest children (0–3 years), who  had
imilar median antibody levels to AMA1 in both cohorts (Fig. 1).
mportantly, the proportion of age-matched children that had anti-
ody concentrations above the protective thresholds was  also
igniﬁcantly lower in Junju compared to Chonyi for AMA1 and
SP-2 except the youngest age-group (Fisher’s exact test P < 0.01).
he proportion of children that had protective threshold antibody
oncentrations against MSP-3 was signiﬁcantly lower in Junju com-
ared to Chonyi only in the 4–5 year age group (Fig. 1).
.4. Protective thresholds explain apparent lack of protection in
he Junju cohort
We  used the protective thresholds derived in the Chonyi cohort
o classify children in the Junju cohort as having antibodies above or
elow threshold concentrations for each antigen. We  then used the
odiﬁed Poisson regression model as previously described, to com-
are the outcome in Junju children classiﬁed in this manner. We
ompared these results with those obtained from analyses based
n seropositive versus seronegative, and high versus low levels. For
ntibodies against AMA1 and MSP-3, we found that the estimates
f risk decreased in a stepwise fashion, when the cutoff was applied
s seropositivity, high levels, and ﬁnally as protective thresholds.
or example, using these three cutoff points in multivariate anal-
ses, antibodies against AMA1 were associated with relative risks
95% conﬁdence intervals) of 1.09 (0.75–1.59), 0.94 (0.65–1.36) and
.16 (0.02–1.12). For both AMA1 and MSP-3, antibody concentra-
ions at the protective thresholds were considerably higher than
hose at seropositive or high levels (Table 2). For antibodies against
SP-2 the reduction in risk was modest across the three categories
f analysis, and there was little difference between the protective
hreshold concentration and that deﬁned by high antibody levels
Table 2). Of note, the proportion of children with antibody concen-
rations above any given cutoff reduced considerably as the cutoff
as raised from sero-positivity, to that deﬁned by high versus low
evels, through to protective thresholds. In the Junju cohort over-
ll, less than 10% of children had antibodies above threshold levels
5.6%, 9.5%, and 6.9% for AMA1, MSP-2 and MSP-3, respectively).
. DiscussionAn increasing body of evidence suggests that protection from
alaria is dependent on high antibody concentrations [5–10]. Our
ata builds on this by using a standardized reference reagent to31 (2013) 3936– 3942 3939
deﬁne the threshold concentration of antibodies for each anti-
gen that was  associated with protection against clinical episodes
of malaria, using data from a high malaria transmission cohort.
Application of these thresholds to an independent moderate trans-
mission cohort provided an explanation for the lack of protection
observed in the latter cohort. Antibody levels in age-matched chil-
dren were signiﬁcantly lower in the moderate (Junju) compared
to those observed in the high (Chonyi) transmission cohort. Con-
sequently, only a small proportion of children in Junju achieved
antibody levels above the protective threshold concentrations.
These data thus provide a plausible biological explanation for the
observation that antibodies to individual antigens are associated
with protection in some cohorts, but not others [4].
Methodological differences between immuno-epidemiological
studies make it difﬁcult to interpret apparently contradictory
results where antibodies to a single antigen are associated with
protection from malaria in one geographical setting, but not in
another [4]. These differences range from deﬁnition of end-points,
whether clinical malaria, time to infection, or malaria with high
parasitaemia, for example, to duration of follow up, quality and
allelic type of antigen tested, whether or not full-length or frag-
ments of antigens were tested, right through to laboratory assays
and analytical approaches, among others. In the current study, we
minimized all these methodological differences and conducted the
studies identically.
There was a clear difference in parasite prevalence rates in chil-
dren aged 2–10 years (PfPR2–10) [23] in the Junju cohort (29%)
compared to Chonyi (44%). Several studies have shown that parasite
prevalence rates in children aged 2–10 years are reliable indica-
tors of malaria endemicity. [23,32–34]. From these studies, areas
of high transmission are deﬁned by a PfPR2–10 of ≥40% whereas
those of low transmission are deﬁned by a PfPR2–10 of <5%. Areas of
intermediate/moderate transmission which would experience an
immediate reduction in parasite prevalence following large scale
deployment of insecticide- treated nets have a PfPR2–10 of 5–40%
[33,35].
Apart from differences in malaria transmission intensity, the
two cohorts belong to the same ethnic group and share similar
environmental factors such as cultivation practices, rainfall, wind
direction, presence of streams and rivers. However, notable differ-
ences between both cohorts were the change in antimalarial drug
policy from sulphadoxine–pyrimethamine to artemether lume-
fantrine in 2006 [36] and the distribution of free insecticide-treated
bednets by the government in the same year [37] increasing cov-
erage from 6% in 1999 [20] to more than 60% [37]. It is plausible
that these factors also contributed to the decline in malaria trans-
mission. In these circumstances, and using a malaria IgG reference
serum to standardize antibody measurements across both cohorts,
we were able to show antibody concentrations in the Junju cohort
were signiﬁcantly lower than those in Chonyi.
Immuno-epidemiological studies have traditionally classiﬁed
study participants as being seropositive or seronegative for
responses to speciﬁc antigens. More recently, we and others have
found that classifying individuals as having high or low levels of
antibodies is a highly informative indicator of protection among
children [5–10]. However, the actual deﬁnition of high versus
low antibody levels varies between studies, making it difﬁcult to
meaningfully compare data from different sites. We  had previ-
ously derived a deﬁnition for high versus low antibody levels that
was  based on the range of responses observed in the cohort under
study [6]. By this deﬁnition, we found that antibody levels which
we would have considered to be high in Junju cohort, were nev-
ertheless lower than those required for protection in the Chonyi
cohort. Thus, an analysis based on high versus low levels in the Junju
cohort would have erroneously concluded that high levels of anti-
bodies against these merozoite antigens were not associated with
3940 L.M. Murungi et al. / Vaccine 31 (2013) 3936– 3942
Fig. 1. Distribution of antibody concentrations in age-matched children recruited from the Chonyi (black) and Junju (grey) cohorts against (A) AMA1, (B) MSP-2 and (C)
MSP-3.  Black dotted and red bold lines represent the protective threshold levels and the median antibody concentrations by age against each antigen, respectively. The
proportion of individuals with antibodies above the protective threshold levels to AMA1 and MSP-2 were signiﬁcantly lower in the Junju compared to Chonyi cohort across
all  age groups, with the exception of the youngest children. (Fisher’s exact test, *P < 0.05, **P < 0.01). For MSP-3, the proportion of individuals with antibodies above the
protective threshold was  signiﬁcantly lower in Junju compared to Chonyi only in the 4–5 year old age category. (For interpretation of the references to colour in this ﬁgure
legend,  the reader is referred to the web version of this article.)
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rotection. We  therefore propose an analytical approach based on
he principle of “protective thresholds” in place of (or in addi-
ion to) seropositivity, or varying deﬁnitions of high versus low
ntibody levels. The protective thresholds concentrations for anti-
odies against each antigen are ﬁxed, and will not vary from one
opulation to the next, allowing for efﬁcient for comparison of data
cross sites. Although our estimates of risk in the Junju cohort did
ot always reach statistical signiﬁcance, we observed a clear trend
n the reduction of risk when the analysis was based on protective
hresholds. In effect, this was a cutoff higher than that conven-
ionally used for seropositivity and/or high versus low levels of
ntibodies. An obvious consequence of raising cutoff points is a
eduction in the ability to detect signiﬁcant effects, as the num-
ers achieving higher antibody concentrations may  be relatively
mall, particularly in areas of low malaria endemicity. The pro-
ective threshold concentration we derived varied by antigen. For
ome antigens, for example AMA1 and MSP-3, this concentration
as considerably higher than that deﬁned by sero-positivity or high
evels. For MSP-2, the protective threshold concentration was  sub-
tantially higher than that deﬁned by seropositivity, but was  nearly
quivalent to what we had previously deﬁned as high levels (high
ntibody level cutoff was 18.5 AU whereas the protective thresh-
ld cutoff was 19 AU). For antibodies against GLURP, the difference
etween the protective threshold concentration and that deﬁned
y sero-positivity, and/or high levels (GLURP-R2) was less marked.
or MSP-119, we were not able to deﬁne a protective threshold by
he methods presented here. These ﬁndings need to be validated in
uch larger cohorts, and in samples collected from different geo-
raphical settings. Efforts in this regard are underway. Additionally
everal studies have shown that quality of antibody responses, in
articular the type of IgG subclasses are also important for protec-
ion [7,10]. We  did not set out to study IgG subclasses in the current
tudy. However, antibodies against the antigens we  have analyzed
ere have been shown from multiple studies to comprise predom-
nantly of the cytophilic IgG1 and IgG3 subclasses [14,16,38] even
n areas of low malaria transmission intensity [39]. Thus although
seful, measurement of IgG subclasses in this study would not have
ltered our interpretation of the data. In the present study, we mea-
ured responses to a single allelic variant of each antigen and did
ot ascertain whether the circulating parasite strains were bearing
he haplotypes tested or whether the strains were similar in the two
ohorts. Although this may  be a potential limitation, our previous
tudies conducted in the same geographical area at different time
oints have found a high correlation between antibodies against
ifferent allelic versions of AMA1 [6,26], MSP-2 [6,40] and MSP-3
6,14]. Furthermore, a longitudinal study conducted in the Gambia
howed that circulating alleles remained stable over time [41].
In conclusion, our data suggests that a “protective threshold”
oncentration of antibodies against speciﬁc merozoite antigens
f P. falciparum needs to be achieved for protection from clinical
pisodes of malaria. We  propose a new approach to the analysis of
uch data that may  add value to current analytical strategies. If val-
dated in larger studies and in unrelated immuno-epidemiological
ohorts, this analytical approach based on “protective thresholds”
ould be usefully extended to the testing of immunogenicity and
otential protective efﬁcacy of sub-unit vaccines currently under
evelopment for malaria.
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